Group 1 - The company has noted the approval of a generic version of its proprietary product Budesonide Enteric-Coated Capsules (Nafukang) by the National Medical Products Administration of China [1] - The original product Nafukang is protected by patent ZL200980127272.5, which is valid until May 7, 2029, and the company has registered this patent information on the Chinese drug patent information registration platform [1] - According to Chinese patent law, any entity or individual must not manufacture, use, promise to sell, sell, or import products that fall under the patent protection without the company's legal permission before the patent expires, or it will constitute patent infringement [1] Group 2 - The company is committed to introducing breakthrough therapies to China to meet urgent medical needs, emphasizing the importance of a robust patent protection system and effective regulations for the sustainable accessibility of innovative drugs [2] - The environment for intellectual property protection in China's pharmaceutical industry has been continuously optimized, providing strong support for pharmaceutical innovation and healthy industry development [2] - The company will continue to collaborate with various parties to respect and uphold intellectual property rights, adhere to relevant laws and regulations, and foster a fair competitive environment to promote the ongoing development and accessibility of innovative drugs for the benefit of Chinese patients [2]
云顶新耀：原研产品耐赋康 的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态